Questcor's Sole Opportunity


In this video, Brenton Flynn describes Questcor Pharmaceuticals' primary opportunity. It's a drug called Acthar, a long acting gel that slowly releases a natural hormone called ACTH. Even though ACTH was approved 60 years ago, Questcor has seen sales of Acthar double this past year, with a projected earnings growth of 20% for the upcoming year. Selling at less than 7.5 times future earnings and paying a 3% dividend, Questcor looks like an attractive value stock.

Learn the full story
Questcor is one of the most debated names in all of biotech. Will insurance companies continue to cover Acthar? Will a government investigation lead to big fines? We highlight these high-profile issues inside our brand new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.

The article Questcor's Sole Opportunity originally appeared on

Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.